Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials
Open Access
- 31 July 2004
- journal article
- review article
- Published by Elsevier BV in American Heart Journal
- Vol. 148 (1), 34-40
- https://doi.org/10.1016/j.ahj.2004.02.004
Abstract
No abstract availableThis publication has 61 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Homocysteine Inhibits TNF-α-Induced Endothelial Adhesion Molecule Expression and Monocyte Adhesion via Nuclear Factor-κB Dependent PathwayBiochemical and Biophysical Research Communications, 2001
- Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor StudytpdelJournal of Internal Medicine, 2000
- Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination surveyAmerican Heart Journal, 2000
- Homocyst(e)ine impairs endocardial endothelial functionCanadian Journal of Physiology and Pharmacology, 1999
- Hyperhomocysteinemia and Hypofibrinolysis in Young Adults With Ischemic StrokeStroke, 1999
- Homocysteine and Cardiovascular DiseaseAnnual Review of Medicine, 1998
- Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate, and folateThe American Journal of Cardiology, 1995
- Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.JCI Insight, 1991